NCT03555578View on ClinicalTrials.gov

"Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

RecruitingOBSERVATIONAL
Enrollment

1,890

Participants

Timeline

Start Date

November 2, 2017

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Spinal and Bulbar Muscular Atrophy
Interventions
DRUG

Leuprorelin Acetate

Leuprorelin Acetate Injection Kit

Trial Locations (1)

Unknown

RECRUITING

Takeda Selected Site, Tokyo

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY

NCT03555578 - "Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)" | Biotech Hunter | Biotech Hunter